•
Jun 28, 2024

Danaher Q2 2024 Earnings Report

Danaher's Q2 2024 financial performance reflected better-than-expected results in revenue, earnings, and cash flow, driven by sustained positive momentum in the bioprocessing business and strong performance at Cepheid.

Key Takeaways

Danaher Corporation reported a decrease in revenue by 3.0% year-over-year to $5.7 billion, with a non-GAAP core revenue decrease of 3.5%. Net earnings were $907 million, or $1.22 per diluted common share, while non-GAAP adjusted diluted net earnings per common share were $1.72. The company's operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.

Net earnings reached $907 million, with diluted EPS at $1.22 and non-GAAP adjusted diluted EPS at $1.72.

Revenues declined by 3.0% year-over-year to $5.7 billion, and non-GAAP core revenue decreased by 3.5%.

Operating cash flow amounted to $1.4 billion, and non-GAAP free cash flow was $1.1 billion.

The company anticipates non-GAAP core revenue to be down low-single digits year-over-year for both the third quarter and full year 2024.

Total Revenue
$5.74B
Previous year: $7.16B
-19.8%
EPS
$1.72
Previous year: $2.05
-16.1%
Core Sales Growth
-3.5%
Previous year: -7%
-50.0%
Gross Profit
$3.43B
Previous year: $4.04B
-15.2%
Cash and Equivalents
$2.37B
Previous year: $8.58B
-72.3%
Free Cash Flow
$1.1B
Previous year: $1.6B
-31.3%
Total Assets
$78.6B
Previous year: $84.9B
-7.5%

Danaher

Danaher

Forward Guidance

The Company anticipates that non-GAAP core revenue will be down low-single digits year-over-year for the third quarter 2024 and continues to expect that non-GAAP core revenue will be down low-single digits year-over-year for full year 2024.